Abstract: 3-Isochromanone is prepared by reacting o-tolyacetic acid with sulphuryl chloride in the presence of a free radical initiator, e.g. AIBN, followed by ring closure of the 2-chloromethylphenylacetic acid so formed with a base, e.g. potassium bicarbonate.

Abstract: A homogeneous method for detecting amplified RNA or DNA target sequences utilizes signal-labelled DNA or RNA probes which show detectably increased fluorescence polarization when hybridized to target sequences. A convenient one-step analytical procedure requiring no nucleic acid extraction or signal separation step is thereby provided.

Abstract: The use of a 2-(C.sub.3-5 -alkyl)-BIT or 2-aralkyl-BIT such as 2-phenylethyl-BIT as a fungicide for plastics materials. 2-n-Butyl-BIT is preferred.

Abstract: A compound of formula (III) ##STR1## is produced by selectively reducing a compound of formula (II) ##STR2## using a reductase possessing the properties of one produced by Beauveria, Candida, Kluyveromyces, Torulaspora or Pichia.orA compound of formula ##STR3## is produced by selectively reducing a compound of formula II using a reductase possessing the properties of one produced by Candida pelliculosa, Neurospora crassa, Pichia trehalophila or preferably Hansenula anomola.

Abstract: A method for making a mold including the steps of (a) forming a layer of a photocurable composition containing a U.V. transparent filler; (b) irradiating the layer formed in step (a) with light in a predetermined pattern thereby forming a solid cross-sectional layer of the desired mold; and (c) repeating steps (a) and (b) on the previously formed solid cross-sectional layer until the mold is formed. The filler is preferably phyllosilicate clay mineral and the mold has heat and pressure shock resistant properties making it particularly useful for injection molding.

Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA are useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: A new and novel solid, microencapsulated product comprising a microencapsulated material contained within a cast, water-soluble, film-forming polymer and the process for preparing such product is disclosed.

Abstract: The present invention provides a process of decontaminating, by composting under specific conditions, soil and/or sediments containing toxic contaminants of TNT, HMX and RDX. The process is carried out by converting the contaminants into harmless materials. The process includes the step of affecting a solid compost mixture during composting with a redox potential below negative 200 mV (millivolts). Further, the process includes several steps which are repeated until complete degradation is achieved. Other processes for degrading compounds such as chlordane, dieldrin, toxaphene, aldrin, endrin, and heptachlorepoxide as well as polychlorinated benzenes are also disclosed.

Abstract: Microcapsules containing a suspension of a solid, biologically active compound in an organic, water-immiscible liquid and processes for their preparation.

Abstract: The invention relates to compounds of formula I and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof and processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. ##STR1## In formula I, A is a ring system in which the --CH(R.sup.3)N(R.sup.2)B--R.sup.1 and --OR.sup.4 groups are positioned in a 1,2 relationship to one another on ring carbon atoms. B is a ring system having R.sup.1 in a 1,3 or 1,4 relationship with the --CH(R.sup.3)N(R.sup.2)-- linking group. R.sup.2 is hydrogen or C.sub.1 -C.sub.6 -alkyl, R.sup.3 is hydrogen, methyl or ethyl, and R.sup.4 is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -cycloalkyl-C.sub.1 -C.sub.3 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl, N-oxides of --NR.sup.2, where chemically possible, or S-oxides of sulphur containing rings, where chemically possible. A, B, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 may be substituted, as defined in the specification.

Abstract: The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methyl-benzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.

Abstract: A composition comprising a cellulosic non-woven material containing a mixture of polymeric biguanides such as poly(hexamethylene biguanide) together with an anionic polymer such as a polyacrylic acid super-absorbent and the use of such composition in disposable articles such as nappies.

Abstract: Compounds of formula I ##STR1## wherein G, J, L, M, m and D have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: A aqueous medium containing a biguanide, particularly a biguanide oligomer, and having a pH of less than 5. The biguanide oligomer may be a poly(hexamethylene biguanide) having up to 15 repeat units. The medium has improved storage stability compared to commercially available systems and is at least as effective as a biocide.

Abstract: An assay for detecting inhibitors of amino acyl-tRNA synthetases by incubating a divalent metal cation, ATP, tRNA, a non-cognate amino acid, inorganic pyrophosphatase and aminoacyl-tRNA synthetase, which aminoacyl-tRNA synthetase is in at least a partially pure form, both with and without a potential inhibitor, converting the resulting pyrophosphate to phosphate, detecting phosphate production, and comparing the phosphate production results obtained.

Abstract: Biocidal proteins capable of isolation from seeds have been characterized. The proteins have an amino acid sequence containing the common cysteine/glycine domain of Chitin-binding Plant Proteins but show substantially better activity against pathogenic fungi, a higher ratio of basic amino acids to acidic amino acids, and/or antifungal activity which results in increased hyphal branching. Antimicrobial proteins isolated from Amaranthus, Capsicum, Briza and related species are provided. The proteins show a wide range of antifungal activity and are active against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants may be transformed with this DNA. The proteins find agricultural or pharmaceutical application as antifungal or antibacterial agents. Transgenic plants expressing the protein will show increased disease resistance.

Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.

Abstract: A process for coloration of a substrate comprising printing an ink onto the substrate using a thermal ink jet printer, characterised in that the ink comprises water and a water-dissipatable polyester dyed using a disperse dye or solvent soluble dye. An ink comprising a water-dissipatable polyester dyed using a disperse dye or solvent dye and an aqueous medium.

Abstract: The invention concerns a compound of formula (I): ##STR1## wherein R.sup.1 -R.sup.6, A, B, and D have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising such a compound or salt, and methods of treating a bacterial infection by administering such a compound or salt.

Abstract: The invention concerns acid derivatives of formula IR.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --Gand pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention also concerns processes for the preparation of the acid derivatives of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.